Heme/Onc KPs2 Flashcards
pembrolizumab MoA? Approved for?
PD-1 inhibitor.
treatment of mismatch-repair deficient tumors (tumors with high microsatellite instability), regardless of the tissue of origin.
Who are candidates for brest cancer prophylaxis?
What are the prophylaxis options?
> 35, 5year risk of 1.7% with lobular carcinoma in situ or atypical ductal hyperplasia
tamoxifen prior to menopause and with tamoxifen, raloxifene, or exemestane after menopause
Women with BRCA1/2 mutations should undergo breast cancer screening when?
MRI beginning at age 25 years and mammography beginning at age 30 years
In patients with estrogen receptor–positive DCIS, this decreases the risk of local recurrence of both DCIS and invasive cancer? Caveat?
adjuvant tamoxifen
no survival benefit
in postmenopausal women younger than 60 years with DCIS, treat with?
anastrozole > tamoxifen
Mastectomy is recommended for?
extra-breast involvement, 2+ breast quadrants, inflammatory breast cancer
How to stage inflammatory breast cancer? Treatment?
CT and bone scan
chemotherapy, followed by surgery, and then radiation
Therapy-related hot flushes in breast cancer survivors may be improved with?
SSRIs, SNRIs
All women with ovarian cancer are eligible for?
BRCA1/2 testing
How to stage ovarian cancer?
surgical exploration
Follow-up for treated ovarain cancer? This has no role
CA-125 monitoring;
no role for continued imaging
Test NOT helping for colon cancer staging?
PET
Treatment of stage III colon cancer?
adjuvant 5-FU + surgery
All patients with metastatic colorectal cancer should undergo tumor genotyping to identify mutations in?
Why?
K-ras and N-ras.
anti–epidermal growth factor receptor antibodies, cetuximab and panitumumab, are inactive in the 50% of tumors that harbor mutations.
Anal cancer is often curable with?
radiation therapy and concurrent chemotherapy with mitomycin plus 5-fluorouracil
Anal cancer - natural course after treatment? Implication?
continue to regress for 6 months to 1 year following completion of radiation therapy
treatment failure should not be declared unless unequivocal growth or metastases are documented
Treatment of metastatic gastroesophageal cancer?
Palliative with cisplant+trastuzaumab if HER-2
General treatment of neuroendocrine tumors?
because so indoluent. can effectively be managed with expectant observation and serial imaging